Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

glaxosmithkline trading services limited, 12 riverwalk, citywest business campus, dublin 24, irska - flutikazonpropionat - sprej za nos, suspenzija - 500 µg/1 g suspenzije, 50 µg/1 inhalacijska doza - urbroj: 1 g suspenzije sadrži 500 mikrograma flutikazonpropionata 1 inhalacijska doza sadrži 50 mikrograma flutikazonpropionata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

stada d.o.o., hercegovačka 14, zagreb, hrvatska - pazopanibklorid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži pazopanibklorid što odgovara 400 mg pazopaniba

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

glaxosmithkline trading services limited, 12 riverwalk, citywest business campus, dublin 24, irska - amoksicilin trihidrat kalijev klavulanat - filmom obložena tableta - 875 mg + 125 mg - urbroj: svaka filmom obložena tableta sadrži 875 mg amoksicilina u obliku amoksicilin trihidrata i 125 mg klavulanske kiseline u obliku kalijevog klavulanata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - levosimendan - koncentrat za otopinu za infuziju - urbroj: 1 ml koncentrata sadrži 2,5 mg levosimendana

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. trostruki kombinovanu terapiju) kao dodatak prehrani i vježbe kod pacijenata, nedovoljno kontroliranim o njihovo maksimalno переносимой doze метформина i sulfonilurejom. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. trostruki kombinovanu terapiju) kao dodatak prehrani i vježbe kod pacijenata, nedovoljno kontroliranim o njihovo maksimalno переносимой doze метформина i sulfonilurejom. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

dr. august wolff gmbh & co. kg arzneimittel, sudbrackstrasse 56, bielefeld, njemačka - benzoilperoksid, s vodom - suspenzija za kožu - 40 mg/g - urbroj: 100 g suspenzije sadržava 5,33 g benzoilperoksida, s vodom (što odgovara 4,0 g benzoilperoksida)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - natrijev betametazonfosfat betametazondipropionat - suspenzija za injekciju - 2 mg+5 mg/1 ml - urbroj: 1 ml suspenzije za injekciju (1 ampula) sadrži 2 mg betametazona u obliku natrijevog betametazonfosfata i 5 mg betametazona u obliku betametazondipropionata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - triamcinolonacetonid - suspenzija za injekciju - 40 mg/ml - urbroj: 1 ml suspenzije za injekciju (1 ampula) sadrži 40 mg triamcinolonacetonida